Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2014-02-25 Interim / Quarterly Rep…
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
2014 Half Year Investor Presentation 16 pages 911.2KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'HY14 Results Presentation' and dated 26 February 2014, indicating it is a half-year (interim) financial results presentation. It contains detailed financial data such as sales revenue, EBITDA, NPAT, segment breakdowns, balance sheet positions, cash flow, and R&D updates. The document is about 15,000 characters long, which is substantial and contains substantive financial data and analysis for the half-year period ending 31 December 2013. The content is consistent with a comprehensive interim or quarterly report rather than a brief earnings release or a simple announcement. It is not a full annual report (10-K) but a half-year report. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). H1 2014
2014-02-25 English
Appendix 3B 9 pages 222.4KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It contains detailed information about the issuance of new fully paid ordinary shares, exercise of options, issue price, and application for quotation on the ASX (Australian Securities Exchange). The content focuses on the issuance and quotation of additional securities, including compliance with ASX rules and warranties related to the securities. There are no financial statements, management discussion, or earnings data present. The document is regulatory in nature, related to capital raising and securities issuance. This matches the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising, financing activities, or capital structure changes. The document length is substantial (12,278 characters), indicating it is the actual announcement, not just a brief notice or report publication announcement. Therefore, the correct classification is CAP with high confidence.
2014-02-25 English
Section 708A notice 1 page 220.7KB
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) regarding the issuance of shares by Mayne Pharma Group Limited. It details the issuance of 22,641,509 fully paid ordinary shares to institutional and sophisticated investors without disclosure under Part 6D.2 of the Corporations Act. The document is a formal regulatory notice about a share placement and compliance with relevant sections of the Corporations Act. It does not contain financial statements, earnings data, or detailed report content. It is an announcement related to capital raising activities, specifically a placement of shares, which fits the category of Capital/Financing Update (CAP). The document length is short and focused on the share issuance notice, not a full report or financial supplement.
2014-02-18 English
Appendix 3B 9 pages 225.3KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It details the issuance of fully paid ordinary shares, the number of securities issued, issue price, purpose of the issue, and related information for ASX (Australian Securities Exchange) compliance. The content focuses on the announcement and application for quotation of new shares, including underwriting and allocation details. There are no financial statements, management discussion, or earnings data present. The document is regulatory in nature, announcing a capital raising event and securities issuance rather than providing a full financial report or earnings release. This fits the category of Capital/Financing Update (CAP).
2014-02-18 English
Completion of placement 2 pages 109.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement about Mayne Pharma successfully completing a placement to raise A$18.0 million. It details the placement price, settlement date, and trading information. There are no financial statements, detailed financial analysis, or management discussion. The document is short (2535 characters) and focuses on the completion of a capital raising event. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2014-02-12 English
Trading Halt 2 pages 384.1KB
Capital/Financing Update Classification · 95% confidence The document is a market release dated 12 February 2014 from Mayne Pharma Group Limited announcing a trading halt requested by the company. The reason for the trading halt is to allow the company to announce an institutional placement to fund an acquisition. The document is short (1858 characters) and does not contain any financial data or detailed report content. It is an announcement related to capital raising activity, specifically a trading halt pending a financing announcement. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2014-02-11 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.